MedTrace Logo

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis

NCT01695408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1232

Last updated 2022-07-27

No results posted yet for this study

Summary

Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years. As in Europe data are limited on the characteristics and management of such patients, INSIGHTS-IPF was initiated as a new registry that documents newly diagnosed (incident) and prevalent patients with confirmed IPF diagnosis prospectively.The registry will contribute to the optimization of the management of IPF patients in the long term.

Conditions

Sponsors & Collaborators

  • GWT-TUD GmbH

    collaborator OTHER

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Juergen Behr, MD, PhD · Ludwig-Maximilian University (LMU) Munich, Med. Clinic V

  • David Pittrow, MD, PhD · Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01695408 on ClinicalTrials.gov